Navigation Links
PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
Date:12/21/2010

60;The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as the CFTR protein in nonsense mutation cystic fibrosis.

The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); FDA's Office of Orphan Products Development; Muscular Dystrophy Association; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

The FDA and the European Commission have granted ataluren Orphan Drug status for the treatment of nonsense mutation cystic fibrosis and nonsense mutation Duchenne and Becker muscular dystrophy.  The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing for CF and dystrophinopathy and Fast Track designation for the development of treatment for nonsense mutation dystrophinopathy.

COLLABORATION WITH GENZYME

PTC Therapeutics has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will commercialize ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world.

ABOUT CYSTIC FIBROSIS (CF)

CF is a life-threatening genetic disorder that causes serious lung infections and digestive complications.  The predicted median age of survival for a person with CF is about 37 years.  According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide.  Genetic testing is required to confirm a complete diagnosis and to determine if a patient's disease is caused by a nonsense mutation.  It is estimated that nonsense mutations are the cause of CF in about 10 percent of patients in the United States and Euro
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
(Date:3/27/2015)... RnRMarketResearch.com adds "Visceral Pain ... report of 52 pages with latest updates, data ... The report "Visceral Pain - Pipeline Review, H1 ... for Visceral Pain, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
(Date:3/26/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... on Omega-3 therapies for cardiovascular disease and overall health, ... common shares of the Corporation (the "Common Shares"). The ... of December 5 th , 2014 to March 4 ... is due on or before April 1, 2015. Interest ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... N.Y., June 13, 2011 Henry Schein, Inc., (NASDAQ: ... and services to office-based practitioners, announced today that ... Schein, and Steven Paladino, the Company,s Executive Vice President and ... Stock Conference.  The conference is taking place at the Four ...
... BOSTON, June 13, 2011 Guidelines that reduce the use ... gentler form of respiratory support can profoundly affect those children,s ... team of researchers at Children,s Hospital Boston. ... of Newborn Medicine at Children,s Hospital Boston and the Neonatal ...
Cached Medicine Technology:Henry Schein to Present at the William Blair 31st Annual Growth Stock Conference 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3
(Date:3/27/2015)... On March 19, 2015, at Detroit’s ... wide receiver Herman Moore, hosted “Fighting Addiction Together,” ... abuse, treatment options and the recent changes in ... ministers and bishops from local churches as well ... “Our ‘Fighting Addiction Together’ luncheon was informative and ...
(Date:3/27/2015)... 27, 2015 The report “CountryFocus: Healthcare, ... source of information on and analysis of the healthcare, ... of the US in 2013 amounted to 316.1 million, ... of 0.8% from 2008. The country’s increasingly elderly population ... will help to boost the growth of the pharmaceutical ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 GenSight, ... it has appointed Sean Fitzgerald, a former technology and ... Operating Officer and Interim Chief Financial Officer. , Mr ... education technology innovator, EverFi, backed by Amazon founder and ... founder Evan Williams. Prior to EverFi, he was a ...
(Date:3/27/2015)... March 27, 2015 GrassrootsHealth, an international ... Our Children (POC) NOW! vitamin D demonstration project April ... of South Carolina (MUSC), and will soon follow with ... at no cost to a minimum of 500 pregnant ... within these two service areas. The project will include ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 When struck ... be hard to know where to begin. The ... Seattle trucking accident attorney, offers accident victims a clear ... legal assistance to ensure their personal injury claim is ... by describing the first actions that should be taken ...
Breaking Medicine News(10 mins):Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... Alzheimer's disease, says a study on mice, but scientists caution ... to people.// ,Jun Wang and other researchers at New ... genes that order the production of amyloid-beta protein, which has ... online edition of science magazine WebMD. ,The researchers ...
... concluded on Tuesday that although organic milk does contain ... milk//, it did not provide any further significant health ... of the evidence on the nutritional differences between organic ... who wrote to the FSA recently asking it to ...
... an effective method of vaccinating mice against infection by ... their study published in October issues of the journal ... the University of Massachusetts Medical School have manipulated the ... is comprised of protein and fatty sugars in the ...
... to health experts, 80% of people suffering from severe ... not even aware of it.// ,Chronic Bronchitis and ... Long-term damage to lung tissue by smoking can lead ... COPD. ,Professor Robert West, director of tobacco ...
... developed a new strain of mice that should help reveal ... a particularly deadly form of acute myeloid leukemia (AML).// ... the Ohio State University Comprehensive Cancer Center (OSUCCC) suggests that ... it over-activates a second gene that helps govern blood cell ...
... tickled at the thought of greens or simply clam up ... reasons// for the delights and aversions to green vegetarian food ... the same, the researchers opine that, this could be the ... nutrients, to be in the pink of health. To understand ...
Cached Medicine News:Health News:80% of lung disease remains ‘undiagnosed’. 2Health News:Mouse Gene With Gene Stutter Will Help Leukemia Research 2Health News:Mouse Gene With Gene Stutter Will Help Leukemia Research 3
Inquire...
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
... The Hall® Surgical MicroChoice® system ... handpieces that may be operated using ... MicroChoice® Handpieces were designed for use ... cutting of bone in a wide ...
Electric Reciprocating Saw, with hand throttle. Can also be purchased without hand throttle (#1915) for use with foot pedal. (#6401-000)...
Medicine Products: